Lexaria Bioscience Corp.
LEXX
$5.11
-$0.76-12.87%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.12% | -1.56% | -47.45% | -105.37% | -134.87% |
| Total Depreciation and Amortization | -5.18% | 22.55% | -8.34% | 6.43% | -32.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.92% | 30.09% | 76.80% | 83.59% | 13.87% |
| Change in Net Operating Assets | -159.33% | -189.06% | 1,085.58% | 83.66% | 188.64% |
| Cash from Operations | 23.45% | -27.00% | -33.91% | -110.73% | -106.85% |
| Capital Expenditure | 39.64% | 39.64% | 100.00% | 42.79% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -133.30% | -117.95% | -77.02% | -50.00% | 53.52% |
| Cash from Investing | -57.72% | -50.22% | -12.82% | -28.84% | 17.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.81% | -12.69% | -59.70% | -41.39% | -41.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.81% | -12.69% | -59.70% | -41.39% | -40.69% |
| Foreign Exchange rate Adjustments | 158.45% | 164.34% | -94.51% | -156.85% | -171.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.12% | -176.03% | -162.00% | -191.26% | -173.03% |